Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed squamous or adenosquamous carcinoma of
the cervix that is metastatic, recurrent, or refractory Any stage disease treated with
prior radical surgery and/or definitive radiotherapy that has locally recurred and is no
longer amenable to surgery or radiotherapy OR Metastatic disease that is not amenable to
surgery or radiation therapy Measurable disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:
Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
Hepatic: Not specified Renal: Creatinine no greater than 1.5 times upper limit of normal
Other: No history of allergic reaction to mannitol Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception during and for 3 months
after study No other prior malignancy except: Adequately treated basal cell or squamous
cell skin cancer In situ cervical cancer Adequately treated stage I or II cancer from
which the patient is currently in complete remission Any other cancer from which the
patient has been disease free for 5 years

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent colony stimulating factor
therapy Chemotherapy: Prior chemotherapy (hydroxyurea, fluorouracil, metronidazole,
cisplatin, or other platinum agent) allowed as a radiosensitizing agent only No other
concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease
Characteristics Prior radiotherapy allowed to less than 30% of the bone marrow only
Recovered from toxic effects No concurrent radiotherapy Surgery: See Disease
Characteristics Prior surgery allowed Recovered from effects of prior surgery Other: No
prior systemic therapy for this disease